| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 13, 2012First Patients Treated in Clinical Trial of Novel Medical Device Involving Interventions for Lower-Extremity Peripheral Artery Disease
MINNEAPOLIS, Apr 13, 2012 (BUSINESS WIRE) --Expanding its commitment to developing innovative treatments for cardiovascular disease and the evidence to support their adoption, Medtronic, Inc....
-
Apr 13, 2012Interactive Tool Simulates Sudden Cardiac Arrest Event; Teaches Crucial Steps in Saving a Life
MINNEAPOLIS, Apr 13, 2012 (BUSINESS WIRE) --The Medtronic Foundation's HeartRescue Project has produced an interactive, online experience, the "Save-a-Life Simulator," to promote proper and timely...
-
Apr 10, 2012Pivotal REVERSE & Landmark RAFT Clinical Trials Demonstrate Reduction in Mortality and Heart Failure Hospitalization Rates in New Patient Population
MINNEAPOLIS--(BUSINESS WIRE)--Apr. 10, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for its cardiac...
-
Mar 30, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 30, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that the company has reached an agreement in principle to settle a previously disclosed federal securities...
-
Mar 26, 2012ACC.12 Late-breaker Shows Promise of Pacemakers through Diminishing Fainting Recurrences in Patients Diagnosed with Syncope
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 26, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered...
-
Mar 25, 2012Data from Two Clinical Trials Presented at the 61st Annual Scientific Session of the American College of Cardiology Show Consistent Effectiveness and Safety Up to Three Years
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 25, 2012-- Medtronic, Inc. (NYSE:MDT), announced that the Symplicity™ renal denervation system provides safe, significant and sustained blood...
-
Mar 24, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic...
-
Mar 24, 2012Recently FDA-Approved, Novel Heart Device Shows Consistently Low Event Rates Across Broad Spectrum of Coronary Artery Disease Patients, Including Those with Diabetes
CHICAGO--(BUSINESS WIRE)--Mar. 24, 2012-- According to new clinical data presented today at ACC.12 –– the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC)...
-
Mar 15, 2012Another Medtronic First in Neuromodulation in Canada
BRAMPTON, Ontario & MINNEAPOLIS--(BUSINESS WIRE)--Mar. 15, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation...
-
Mar 14, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 14, 2012-- Medtronic, Inc. (NYSE:MDT) today announced a registered offering of $675 million of its 3.125% Senior Notes due 2022 and $400 million of its 4.50%...
-
Mar 7, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 7, 2012-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Barclays Capital Global...
-
Mar 5, 2012CapSure Sense MRI™ SureScan® Passive Fixation Leads Gives Physicians More MR-Conditional Options
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 5, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the receipt of CE Mark (Conformité Européenne) and launch of the CapSure Sense MRI™ SureScan® pacing...
-
Mar 1, 2012“Global Heroes” Will Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 1, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it is recruiting runners from around the world who benefit from medical technology to participate in the...
-
Feb 29, 2012World’s First Insulin Pump with Low Glucose Suspend Showed Reduces Time Spent in Low Threshold Range
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 29, 2012-- In the next step toward the development of an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced that the results of the in-clinic ASPIRE...
-
Feb 23, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 23, 2012-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Citi Healthcare Conference...
-
Feb 21, 2012Revenue of $3.9 Billion Driven by International Revenue Growth of 6% on a Constant Currency Basis, 7% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 21, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2012, which ended January 27, 2012. The company...
-
Feb 17, 2012Distinguished by Superior Deliverability and Diabetes Indication, New Heart Device Becomes Available to Cath Labs Nationwide
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 17, 2012-- Advancing the clinical practice of interventional cardiovascular medicine, Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (
-
Feb 16, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 16, 2012-- The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.2425 per share of the Company’s common stock. The dividend...
-
Feb 13, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 13, 2012-- Medtronic, Inc. (NYSE: MDT) announced today the start of two clinical initiatives evaluating the broader, real-world clinical use of the company’s...
-
Feb 10, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 10, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2012 on Tuesday, February 21,...
-
Feb 8, 2012New Clinical Data Presented for First Time at Medical Meetings in U.S. and Europe Show Durable Vessel Patency in Treating Atherosclerotic Lesions of Superficial Femoral Artery
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 8, 2012-- Consistent with its commitment to developing better treatments for peripheral arterial disease (PAD), Medtronic Inc. (NYSE:MDT) today announced the...
-
Feb 1, 2012IMPROVE HF Bridge Study Will Examine Specific Gaps in Implementation of Guideline-Recommended Treatment in Heart Failure Patients Post-Hospital Discharge
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 1, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the initiation and first patient enrollment in a clinical study that will evaluate gaps in the...
-
Jan 30, 2012New System Builds On Sprint Quattro® Lead, Adding to the Company’s Portfolio of Innovative Technologies Proven to Treat Heart Rhythm Disorders
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 30, 2012-- Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a...
-
Jan 30, 2012Multicenter Experience Demonstrates Surgical Approach, with Recent CE Mark, is a Feasible Alternative for Transcatheter Aortic Valve Implantation
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 30, 2012-- Medtronic, Inc. (NYSE: MDT) today issued a statement on the results of two studies evaluating the use of the Medtronic CoreValve® System delivered...
-
Jan 30, 2012Multicenter Experience Demonstrates Surgical Approach, with Recent CE Mark, is a Feasible Alternative for Transcatheter Aortic Valve Implantation
MINNEAPOLIS, Jan 30, 2012 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today issued a statement on the results of two studies evaluating the use of the Medtronic CoreValve(R) System delivered...